Our Approach

MGL-3196

MGL-3196 is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist. Preclinical, toxicology, Phase 1 and Phase 2 clinical data suggest MGL-3196 has an attractive, differentiated profile as a potential treatment for non-alcoholic steatohepatitis (NASH) and dyslipidemias, including heterozygous familial hypercholesterolemia (HeFH).

THR-β selectivity also enhances the safety profile of MGL-3196, compared to non-selective agents. MGL-3196 has shown no suppression of the central thyroid axis, no THR-α effects on heart rate or bone, and no elevation of liver enzymes. These characteristics make MGL-3196 among the most promising molecules in development in this therapeutic area.

NASH Phase 2 Clinical Trial

In Madrigal’s Phase 2 clinical trial, MGL-3196 achieved statistically significant results in the primary endpoint, the relative reduction of liver fat on magnetic resonance imaging-estimated proton density fat fraction, or MRI-PDFF, at 12-weeks. Statistically significant results were also achieved in multiple Week 36 endpoints, including key secondary endpoints, reduction and resolution of NASH:

  • More patients treated with MGL-3196 compared with placebo achieved a two-point reduction in NAS (NAFLD activity score) on biopsy and resolution of NASH on biopsy.
  • More patients treated with MGL-3196 compared with placebo achieved resolution of NASH on biopsy.
  • MGL-3196 treated patients with > 30% reduction on MRI-PDFF at Week 12 demonstrated a higher percentage of NAS reduction and NASH resolution.
  • In patients with NASH resolution, 35% of MGL-3196 treated and no placebo patients had baseline NAS ≥5.
  • In MGL-3196 patients with NASH resolution, fibrosis also resolved (i.e., fibrosis stage 0) in 50% of patients and was decreased statistically significantly relative to all placebo patients.
  • MGL-3196 treated patients had sustained, highly statistically significant (p<0.0001) reductions in liver fat compared with placebo on Week 36 MRI-PDFF, and mean relative fat reduction MGL-3196 (37% compared with placebo, 8.9%).
  • MGL-3196 was well-tolerated with mostly mild and a few moderate AEs, which were balanced between drug treated and placebo patients.

HeFH Phase 2 Clinical Trial
In a completed Phase 2 clinical trial, MGL-3196 demonstrated statistically significant improvement in the reduction of LDL cholesterol (LDL-C) compared to placebo – the primary endpoint of this 12-week trial in HeFH patients on maximal statin therapy:

  • MGL-3196 treated patients (placebo corrected) achieved highly significant (p< 0.0001) LDL-C lowering of 18.8%, and 21% LDL-C lowering in those on an optimal dose of MGL-3196. LDL-C lowering was 28.5% in MGL-3196 treated compared to placebo in a prespecified group of patients who did not tolerate high intensity statin doses.
  • Other statistically significant results achieved for MGL-3196 compared to placebo for multiple secondary endpoints included reduction of triglycerides, apolipoprotein B (ApoB), and lipoprotein(a) (Lp(a)), a highly atherogenic lipid particle commonly elevated in HeFH patients and not adequately controlled by existing therapies.
  • MGL-3196 was well tolerated in this trial as compared to placebo with mostly mild and some moderate AEs balanced between drug-treated and placebo patients.

MGL-3196 Phase 3 Clinical Program

Based on evidence of broad activity and a favorable safety profile, Madrigal plans to initiate a Phase 3 clinical program in NASH and a second Phase 3 clinical program in a broader segment of patients with dyslipidemia, including potentially patients with earlier stages of fatty liver disease who, like the later stage NASH patients, are at high risk of cardiovascular disease.

Learn More